Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2023

30.09.2022 | COVID-19 | Original Article

Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan

verfasst von: Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with inflammatory bowel disease (IBD) are recommended to receive the coronavirus disease 2019 (COVID-19) vaccine. However, a recent survey showed that patients with IBD are more hesitant to receive the vaccine than the general population. Detailed information on the side effects of the COVID-19 vaccine is necessary to encourage vaccination among patients with IBD.

Aim

To investigate the frequency of side effects following COVID-19 vaccination in patients with IBD in Japan. Study design: a cross-sectional survey was conducted using a questionnaire administered to adult patients with IBD in a tertiary medical facility.

Results

Among the participants who answered the questionnaire, 92.6%, 91.5%, and 41.5% of the participants had received their first, second, and third doses of the COVID-19 vaccine, respectively. Of the vaccinated participants, 88.3%, 86.3%, and 89.0% experienced side effects after receiving the first, second, and third doses of the vaccine, respectively. The incidences of fever, chills, and headaches were significantly higher among female participants than among male participants (p < 0.05). However, the frequencies of most side effects were comparable between the BNT162b2 mRNA and mRNA-1273 vaccines.

Conclusion

The findings of our survey can help encourage patients with IBD to receive the COVID-19 vaccine.
Literatur
1.
Zurück zum Zitat Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19: 141–154.CrossRef Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19: 141–154.CrossRef
2.
Zurück zum Zitat Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.CrossRef Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.CrossRef
3.
Zurück zum Zitat Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–478.CrossRef Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–478.CrossRef
4.
Zurück zum Zitat Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020; 395: 689–697.CrossRef Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020; 395: 689–697.CrossRef
5.
Zurück zum Zitat Hui DS, Esam IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264–266.CrossRef Hui DS, Esam IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264–266.CrossRef
6.
Zurück zum Zitat Zhao J, Zhao S, Ou J, et al. COVID-19: coronavirus vaccine development updates. Front Immunol 2020; 11: 602256.CrossRef Zhao J, Zhao S, Ou J, et al. COVID-19: coronavirus vaccine development updates. Front Immunol 2020; 11: 602256.CrossRef
7.
Zurück zum Zitat He Q, Mao Q, Zhang J, et al. COVID-19 Vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol 2021; 12: 669339.CrossRef He Q, Mao Q, Zhang J, et al. COVID-19 Vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol 2021; 12: 669339.CrossRef
8.
Zurück zum Zitat Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case–control study. BMJ 2021; 373: n1088.CrossRef Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case–control study. BMJ 2021; 373: n1088.CrossRef
9.
Zurück zum Zitat Rabail R, Ahmed W, Ilyas M, et al. The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines (Basel) 2022; 10: 488.CrossRef Rabail R, Ahmed W, Ilyas M, et al. The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines (Basel) 2022; 10: 488.CrossRef
10.
Zurück zum Zitat Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021; 385: 2348–2360.CrossRef Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021; 385: 2348–2360.CrossRef
11.
Zurück zum Zitat Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416.CrossRef Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416.CrossRef
12.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603–2615.CrossRef Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603–2615.CrossRef
13.
Zurück zum Zitat Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2021; 384: 1576–1577.CrossRef Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2021; 384: 1576–1577.CrossRef
14.
Zurück zum Zitat Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385: 1761–1773.CrossRef Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385: 1761–1773.CrossRef
15.
Zurück zum Zitat Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 2021; 106: 376–381.CrossRef Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 2021; 106: 376–381.CrossRef
16.
Zurück zum Zitat Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 2021; 93: 4420–4429.CrossRef Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 2021; 93: 4420–4429.CrossRef
17.
Zurück zum Zitat Yoda T, Katsuyama H. Willingness to receive COVID-19 vaccination in Japan. Vaccines (Basel) 2021; 9: 48.CrossRef Yoda T, Katsuyama H. Willingness to receive COVID-19 vaccination in Japan. Vaccines (Basel) 2021; 9: 48.CrossRef
18.
Zurück zum Zitat Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum Vaccines Immunother. 2021;17:1612–1621.CrossRef Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum Vaccines Immunother. 2021;17:1612–1621.CrossRef
19.
Zurück zum Zitat Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol 2021; 116: 1746–1751. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol 2021; 116: 1746–1751.
20.
Zurück zum Zitat Doherty J, Fennessy S, Stack R, et al. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021; 54: 1110–1123.CrossRef Doherty J, Fennessy S, Stack R, et al. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021; 54: 1110–1123.CrossRef
21.
Zurück zum Zitat Walldorf J, von Arnim U, Schmelz R, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease—fear and desire. Inflamm Bowel Dis. 2021; 27: 1858–1861.CrossRef Walldorf J, von Arnim U, Schmelz R, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease—fear and desire. Inflamm Bowel Dis. 2021; 27: 1858–1861.CrossRef
22.
Zurück zum Zitat Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 vaccination intent and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2021; 19: 1730-1732.e1732.CrossRef Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 vaccination intent and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2021; 19: 1730-1732.e1732.CrossRef
23.
Zurück zum Zitat Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021; 4: e2140364.CrossRef Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021; 4: e2140364.CrossRef
24.
Zurück zum Zitat Haas JW, Bender FL, Ballou S, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e2143955.CrossRef Haas JW, Bender FL, Ballou S, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e2143955.CrossRef
25.
Zurück zum Zitat Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385: 187–189.CrossRef Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385: 187–189.CrossRef
26.
Zurück zum Zitat Abu-Halaweh S, Alqassieh R, Suleiman A, et al. Qualitative assessment of early adverse effects of Pfizer-BioNTech and Sinopharm COVID-19 vaccines by telephone interviews. Vaccines (Basel) 2021; 9: 950.CrossRef Abu-Halaweh S, Alqassieh R, Suleiman A, et al. Qualitative assessment of early adverse effects of Pfizer-BioNTech and Sinopharm COVID-19 vaccines by telephone interviews. Vaccines (Basel) 2021; 9: 950.CrossRef
27.
Zurück zum Zitat Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel) 2022; 10: 223.CrossRef Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel) 2022; 10: 223.CrossRef
28.
Zurück zum Zitat Loosen SH, Bohlken J, Weber K, et al. Factors associated with non-severe adverse reactions after vaccination against SARS-CoV-2: a cohort study of 908,869 outpatient vaccinations in Germany. Vaccines (Basel) 2022; 10: 566.CrossRef Loosen SH, Bohlken J, Weber K, et al. Factors associated with non-severe adverse reactions after vaccination against SARS-CoV-2: a cohort study of 908,869 outpatient vaccinations in Germany. Vaccines (Basel) 2022; 10: 566.CrossRef
29.
Zurück zum Zitat Paczkowska A, Hoffmann K, Michalak M, et al. Safety profile of COVID-19 vaccines among healthcare workers in Poland. Vaccines (Basel) 2022; 10: 434.CrossRef Paczkowska A, Hoffmann K, Michalak M, et al. Safety profile of COVID-19 vaccines among healthcare workers in Poland. Vaccines (Basel) 2022; 10: 434.CrossRef
30.
Zurück zum Zitat Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 2021; 25: 1663–1669. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 2021; 25: 1663–1669.
Metadaten
Titel
Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan
verfasst von
Haruka Miyazaki
Daisuke Watanabe
Yuki Ito
Norihiro Okamoto
Eri Tokunaga
Yuna Ku
Makoto Ooi
Namiko Hoshi
Yuzo Kodama
Publikationsdatum
30.09.2022
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07703-5

Weitere Artikel der Ausgabe 2/2023

Digestive Diseases and Sciences 2/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.